Confo Therapeutics
Filip is a member of the Board of Directors of Confo Therapeutics, Virovet, and Remynd.
Filip is a Senior Investment Manager at Participatie Maatschappij Vlaanderen (PMV), with investment interests related to therapeutics and medical devices. Filip joined PMV from Vives, where he was an investment manager responsible for the life science franchise, and a member of the Board in Syndesi, Virovet and Aphea. He was further involved in – among others – Novadip, and the road towards IPO of iTeos Therapeutics (NASDAQ:ITOS). Prior to Vives, Filip held corporate positions in both small biotech as well as larger pharmaceutical companies.
Filip obtained a PhD in Pharmaceutical Sciences from Antwerp University (Belgium), a degree in Clinical Biology (Type A), Business Administration (IPO, Antwerp), and CEIPI certificate in Patent Law (U. Strassbourg, France).
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Confo Therapeutics
1 followers
Confo Therapeutics is an emerging drug discovery company built around a disruptive technology to enable the discovery of GPCR agonists. The CONFO® technology uses single domain antibodies to lock inherently unstable GPCRs in the druggable conformation and uses this stabilized complex as a superior starting point for GPCR drug discovery.